Drugs / GenSci004
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06007417 | Dec 2023 → May 2025 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06007417 ↗ |
| Known as | PEG-somatropin | “GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)” NCT06007417 ↗ |
| Modality | Protein / enzyme biologic | “GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)” NCT06007417 ↗ |